Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q2 FY2026 Earnings Presentation
21 slides from Morepen Laboratories's earnings presentation, Nov 14, 2025
Slide 1: Exchange filing cover letter: Investor Presentation Q2 FY26
Date: 14/11/2025 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Presentation – Q2’ FY26 Dear Sir/ Madam, Please
Slide 2: Q2'FY26 Investor Presentation
Q2'FY26 investor presentation MOREPEN LABORATORIES LIMITED
Slide 3: Safe Harbour
SAFE HARBOUR This investor presentation has been prepared for general information purposes in respect of Morepen Laboratories Limited (“Company”) together with its subsidiary, as applicable (together, with the Company, the “Group”) only, without regard to any specific objectives, suitability, financ
Slide 4: Executive Summary
EXECUTIVE sUmMMaARY
Slide 5: Executive Summary: Business Segments
1 Executive Summary Q2'FY 26 Business Segments: standAlone Medical Devices Pharma Business Point of Care API+Rx 34% 66% Share of Medical Share of Pharma Devices Business
Slide 6: Executive Summary: Standalone Revenue
1 Executive Summary Q2'FY 26 standalone revenue: H1 Revenue quarterly Revenue Rs. in Crores Rs. in Crores 800 777 770 400 388 374 600 300 400 200 200 100 0 0 H1'25 H1'26 Q2'FY25 Q2'FY26
Slide 7: Medical Devices
2 Medical devices Q2'FY 26
Slide 8: Medical Devices: Top Selling Products
2 Medical Devices Q2'FY 26 Top selling Products: Blood Glucose meters BP Monitors Nebulisers Thermometers Ortho supports Pregnancy Kits
Slide 9: Medical Devices: Total Revenue
2 Medical Devices Q2'FY 26 Total revenue : H1 quarterly Revenue Rs. in Crores Rs. in Crores 287 140 133 300 126 271 120 250 100 200 80 150 60 100 40 50 20 0 0 H1'25 H1'26 Q2'FY25 Q2'FY26
Slide 10: Glucometer Revenue
2 Medical Devices Q2'FY 26 glucometer revenue : quarterly Revenue Rs. in Crores 120 103 100 97 16.1 mn 80 60 gluco meters sold Happy customer base 40 20 0 Q2'FY25 Q2'FY26
Slide 11: BP Monitor Revenue
2 Medical Devices Q2'FY 26 BP Monitor revenue : quarterly Revenue Rs. in Crores 25 23 23 20 #1 15 10 Market Leaders for BP Monitors 5 0 Q2'FY25 Q2'FY26
Slide 12: Pharma Business
3 Pharma Business
Slide 13: Total Pharma Revenue
3 Pharma Business Q2'FY 26 Total Pharma revenue : H1 Revenue quarterly Revenue Rs. in Crores Rs. in Crores 600 506 483 248 500 250 235 400 200 300 150 200 100 100 50 0 0 H1'25 H1'26 Q1'FY26 Q2'FY26
Slide 14: Pharma Business/API: Product-wise Breakup
3 pHarma Business/API Q2'FY 26 Product-wise breakup: Others Monte 13.7% 13% Dapa 4% PRODUCT share Rosu API revenue split Q2'FY26 Lorata +Des 12.4% 24.4% Fexo 4.7% Atorva 27.7%
Slide 15: Pharma Business/API: Continent-wise Share
3 pHarma Business/API Q2'FY 26 Continent-wise share: S. America USA S. America USA 3.4% 14.8% 3.6% 12.7% India India 28.5% 26.9% H1'26 Q2 FY 26 Europe Europe 30.6% 31.6% Asia Asia 21.7% 26.2%
Slide 16: API Revenue
2 Pharma Business/API Q2'FY 26 API revenue : h1 Revenue quarterly Revenue Rs. in Crores Rs. in Crores 500 455 250 424 219 400 205 200 300 150 200 100 100 50 0 0 H1'25 H1'26 Q1'FY26 Q2'FY26
Slide 17: Finished Dosages: Rx Branded Formulation
2 pHarma Business/Finished Dosages Q2'FY 26 Rx : Branded Formulation quarterly Revenue Rs. in Crores 30 29 25 24 new products 20 consistent growth 15 10 5 0 Q2'FY25 Q2'FY26
Slide 18: Financial Overview
Q2'FY 26 4 financial Overview
Slide 19: Quarterly Performance: Standalone
4 Financial Overview Q2'FY 26 Quarterly Performance: STANDALONE Rs. in Crores Gross Revenue EBITDA PAT 395 : 400 374 35 33 20 30 300 14 25 23 15 20 200 10 15 8 100 10 5 5 0 0 0 Q1'FY26 Q2'FY26 Q1'FY26 Q2'FY26 Q1'FY26 Q2'FY26
Slide 20: Quarterly Performance: Consolidated
4 Financial Overview Q2'FY 26 Quarterly Performance: consolidated Rs. in Crores Gross Revenue EBITDA PAT : 500 40 430 416 35 50 400 41 30 29 40 300 30 20 200 20 10 11 100 10 0 0 0 Q1'FY26 Q2'FY26 Q1'FY26 Q2'FY26 Q1'FY26 Q2'FY26
Slide 21: Thank you
MOREPEN Indilk YUU www.morepen.com
Morepen Laboratories — Q2 FY2026 Earnings Presentation on 6ix